valproic acid has been researched along with metronidazole in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alterthum, K; Bauer, P; Stünkel, S; Windorfer, A | 1 |
| Cai, S; Castela-Papin, N; Farinotti, R; Keller, F; Souleau, CH; Vatier, J | 1 |
| Aebischer, B; Akboga, MK; Akdamar, G; Alcalay, RN; Álvarez-Pérez, S; Aydogdu, S; Balci, KG; Barcaro, G; Bišová, K; Blanco, JL; Brewer, SH; Caruthers, SD; Ceylan, O; Chadwick, JA; Chang, DD; Che, JM; Chen, QQ; Chen, W; Chen, Z; Chung, M; Chung, W; Colecraft, HM; Coteli, E; Dogan, H; Dong, S; Elsig, S; Fahn, S; Fang, XJ; Feng, MG; Fenlon, EE; Floyd, KT; Fokdal, L; Ford, B; Fortunelli, A; Freudenberg, R; Gan-Or, Z; García, ME; Gillham, C; Giovannelli, D; Goertz, RS; Gulati, V; Haie-Meder, C; Hao, YY; Hatano, K; Hines, KJ; Hines, SM; Hirakawa, H; Hoskin, P; Hu, JH; Huang, P; Huang, Y; Hubicka, U; Inoue, Y; Ishii, N; Janssen, PM; Jin, Z; Johnson, A; Jürgenliemk-Schultz, I; Kaineder, K; Kamei, K; Kang, U; Karatas, F; Kash, TL; Katayama, Y; Keupp, J; Kirisits, C; Kisacik, H; Kodama, K; Kotzerke, J; Kryczyk, A; Kuhness, D; Kuo, S; Lanza, GM; Le Bris, N; Levin, DE; Levy, OA; Li, B; Li, H; Li, X; Liang, GD; Liang, Y; Liao, RQ; Lin, JT; Lindegaard, JC; Liong, C; Liu, B; Liu, C; Liu, GH; Liu, L; Liu, Q; Liu, X; Lowe, J; Lowery-Gionta, EG; Ma, YH; Maden, O; Mankad, V; Marder, KS; Marshall, SA; Martínez-Nevado, E; Maucksch, U; Mazeron, R; Mazzone, CM; Mazzoni, P; Mezricky, D; Mizokami, Y; Naumann, A; Navarro, M; Netzer, FP; Neurath, MF; Nie, Q; Oliva, P; Ozeke, O; Peláez, T; Pfeifer, L; Pleil, KE; Pomp, S; Pötter, R; Puckerin, AA; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Řezanka, M; Řezanka, T; Rinker, JA; Rouleau, GA; Runge, R; Sahin, MD; Sakai, A; Schmieder, AH; Schmitz, AJ; Schultz, EJ; Šegedin, B; Sementa, L; Shen, Y; Shiotsuki, I; Shirahama, M; Staley, J; Starovoytov, V; Sterrer, M; Strobel, D; Sturdza, A; Subramanyam, P; Surnev, S; Swager, SA; Taeymans, J; Tan, H; Tan, LT; Tanderup, K; Temizhan, A; Terao, T; Thiele, TE; Tran, T; Tucker, MJ; Vetriani, C; Vítová, M; Wang, JP; Wang, L; Wang, M; Wang, X; Waters, CH; Weng, SX; Wickline, SA; Wildner, D; Wodarcyk, AJ; Wolf, P; Wu, L; Wu, YL; Wunderlich, G; Xiong, L; Xu, P; Yang, GS; Yang, XN; Yang, Y; Yayla, C; Ying, SH; Zachleder, V; Zhang, XG; Zhang, XK; Zhang, Y; Zheng, JY; Zhong, WZ; Zhu, J; Zhu, YJ; Żmudzki, P | 1 |
2 review(s) available for valproic acid and metronidazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; Animals; Animals, Zoo; Anti-Bacterial Agents; Anticoagulants; Antifungal Agents; Antimanic Agents; Antioxidants; Aortic Valve; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bacillus; Bacterial Toxins; Bacterial Typing Techniques; Base Composition; Beauveria; Binge Drinking; Biomarkers; Bipolar Disorder; Blood Coagulation; Blotting, Western; Brachytherapy; Calcium Channels, L-Type; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Wall; Cells, Cultured; Ceramics; Chi-Square Distribution; China; Chlorophyll; Chlorophyta; Chloroplasts; Cholesterol, HDL; Chromatography, High Pressure Liquid; Chromobacterium; Clostridium perfringens; Clozapine; Constriction, Pathologic; Coronary Artery Bypass; Corticotropin-Releasing Hormone; Cross-Sectional Studies; Cytochrome P-450 CYP2C9; Dental Porcelain; Dental Restoration Failure; Dental Stress Analysis; Designer Drugs; Diaminopimelic Acid; DNA Fingerprinting; DNA, Bacterial; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Dosage Calculations; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Elasticity Imaging Techniques; Epsilonproteobacteria; Equipment Design; Ericaceae; Excitatory Amino Acid Antagonists; False Negative Reactions; Fatty Acids; Female; Food Analysis; Fresh Water; Gene Expression Regulation, Neoplastic; Glutathione; Graft Occlusion, Vascular; Heart Valve Prosthesis Implantation; Heart Ventricles; HEK293 Cells; Hemolymph; Humans; Hyaluronan Receptors; Hydrogen Peroxide; Hydrothermal Vents; Indoles; Inflammation Mediators; Inhibitory Concentration 50; Insecta; International Normalized Ratio; Isotope Labeling; Itraconazole; Kidney; Kinetics; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lamotrigine; Lanthanoid Series Elements; Limit of Detection; Linear Models; Lipid Peroxidation; Liver; Liver Cirrhosis; Logistic Models; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Malondialdehyde; Mediastinum; Metronidazole; Mice; Mice, Nude; Mice, Transgenic; Microbial Sensitivity Tests; Microscopy, Fluorescence; Middle Aged; Monocytes; Monomeric GTP-Binding Proteins; Multivariate Analysis; Myocytes, Cardiac; Neoplasm Staging; Neoplastic Stem Cells; Neural Pathways; Nitrates; Nucleic Acid Hybridization; Octamer Transcription Factor-3; Odds Ratio; Oxidation-Reduction; Oxidative Stress; Peptidoglycan; Phantoms, Imaging; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Phospholipids; Photolysis; Photosynthesis; Phylogeny; Plant Extracts; Polychaeta; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Preoperative Care; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyrimidines; Pyrroles; Quorum Sensing; Radiology, Interventional; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Reference Values; Regression Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhizosphere; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Rutin; Saphenous Vein; Seawater; Selenium; Semen Preservation; Sensitivity and Specificity; Septal Nuclei; Sequence Analysis, DNA; Serum Albumin; Serum Albumin, Human; Shear Strength; Sodium Pertechnetate Tc 99m; Sodium-Hydrogen Exchangers; Soil Microbiology; SOXB1 Transcription Factors; Spain; Species Specificity; Sperm Motility; Spermatozoa; Spheroids, Cellular; Spores, Fungal; Stroke; Superoxide Dismutase; Swine; Tandem Mass Spectrometry; Technetium Compounds; Technetium Tc 99m Exametazime; Technetium Tc 99m Sestamibi; Temperature; Thiosulfates; Thrombosis; Thyroid Neoplasms; Transducers; Transfection; Transplantation, Heterologous; Treatment Outcome; Triazines; Tumor Burden; Urocortins; Uterine Cervical Neoplasms; Vacuoles; Valproic Acid; Ventral Tegmental Area; Vitamin K 2; Vitamin K Epoxide Reductases; Warfarin; Water Microbiology; Young Adult | 2016 |
13 other study(ies) available for valproic acid and metronidazole
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
[Effects of drug interaction in infancy (author's transl)].
Topics: Carbamazepine; Child; Chloramphenicol; Clonazepam; Dexamethasone; Drug Interactions; Humans; Isoniazid; Metronidazole; Phenobarbital; Phenytoin; Sulfonamides; Valproic Acid | 1980 |
Drug interactions with diosmectite: a study using the artificial stomach-duodenum model.
Topics: Adsorption; Animals; Anti-Infective Agents; Cimetidine; Dapsone; Digoxin; Drug Interactions; Duodenum; Fluoroquinolones; Gastric Mucosa; Gastrointestinal Agents; Hydrogen-Ion Concentration; Intestinal Absorption; Metronidazole; Models, Biological; Pharmacokinetics; Silicates; Stomach; Swine; Valproic Acid | 1999 |